This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 133.33% and 0.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of 15.79% and 4.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 55.56% and 7.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -11.54% and 0.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Artivion (AORT) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 200% and 5.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.
Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Medical Stocks Lagging Artivion (AORT) This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.
3 Buy-Rated Small Caps Flexing Big Growth
by Derek Lewis
Small-cap stocks can be solid considerations for those who can handle a higher level of volatility. Analysts have recently become bullish on these three.
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Artivion (AORT) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 184.62% and 4.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Artivion (AORT) have performed compared to their sector so far this year.
Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Intuitive Surgical, Inc. (ISRG) and Artivion (AORT) have performed compared to their sector so far this year.
Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AN2 Therapeutics, Inc. (ANTX) and Artivion (AORT) have performed compared to their sector so far this year.
Wall Street Analysts Believe Artivion (AORT) Could Rally 44.41%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 44.4% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Augmedix, Inc. (AUGX) have performed compared to their sector so far this year.
Molina Healthcare (MOH) Wins Medicaid Deal From New Mexico HSD
by Zacks Equity Research
Molina Healthcare (MOH) receives a contract from the New Mexico HSD, subsequent to which it can effectively serve the statewide Medicaid members.
Time to Buy These Medical Stocks as Earnings Approach
by Shaun Pruitt
Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.